9 METERS BIOPHARMA, INC.

$ Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000155198620000050 Filed on March 20, 2020

Income Statement

Concept	2020 Q1	2019	2018 Q4

Balance Sheet

Concept	2020 Q1	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.670M	$4.590M	$5.730M
YoY Change	-76.76%	-19.9%	1232.56%
Cash & Equivalents	$2.668M	$4.590M	$5.729M
Short-Term Investments
Other Short-Term Assets	$570.0K	$640.0K	$680.0K
YoY Change	-41.84%	-5.88%	1260.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.231M	$5.220M	$6.414M
YoY Change	-74.1%	-18.56%	752.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.14K	$70.00K	$35.10K
YoY Change	-32.77%	75.0%	-13.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.580K	$10.00K	$5.580K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$54.70K	$80.00K	$40.68K
YoY Change	-53.46%	100.0%	-12.12%
TOTAL ASSETS
Total Short-Term Assets	$3.231M	$5.220M	$6.414M
Total Long-Term Assets	$54.70K	$80.00K	$40.68K
Total Assets	$3.286M	$5.300M	$6.454M
YoY Change	-73.9%	-17.83%	708.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.075M	$3.890M	$3.619M
YoY Change	29.19%	7.46%	36.11%
Accrued Expenses	$4.848M	$4.790M	$826.3K
YoY Change	440.29%	415.05%	-29.99%
Deferred Revenue
YoY Change
Short-Term Debt	$4.300M	$3.180M	$5.200M
YoY Change	14.97%	-38.85%	282.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.84M	$14.91M	$10.11M
YoY Change	44.7%	47.48%	-22.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.84M	$14.91M	$10.11M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$15.84M	$14.91M	$10.11M
YoY Change	44.36%	47.48%	281.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$74.17M		-$43.52M
YoY Change	54.67%		124.85%
Common Stock	$4.133K		$2.609K
YoY Change	33.02%		-78.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.55M	-$9.610M	-$3.659M
YoY Change
Total Liabilities & Shareholders Equity	$3.286M	$5.300M	$6.454M
YoY Change	-73.9%	-17.83%	708.3%

Cashflow Statement

Concept	2020 Q1	2019	2018 Q4

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.10
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-3659064	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-9614014	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4921000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6624200	USD
CY2019Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24762151	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33328591	shares
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. While cash held by financial institutions may at times exceed federally insured limits, management believes that no material credit or market risk exposure exists due to the high quality of the financial institutions. The Company has not experienced any losses on such accounts.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2019	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Liability </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">The Company accounts for derivative instruments in accordance with Accounting Standards Codification (“ASC”) 815, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative and Hedging, </font><font style="font-family:inherit;font-size:10pt;">which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value. The Company’s derivative financial instrument consists of an embedded option in the Company’s convertible debt. The embedded derivative includes provisions that provide the noteholder with certain conversion and put rights at various conversion or redemption values as well as certain call options for the Company. See Note 6—Debt for further details.</font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets and management’s assessment of the Company’s ability to continue as a going concern. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</font></div></div>
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018Q4	innt	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	58151	USD
CY2019Q4	innt	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	4143269	USD
CY2018	innt	Accrued Milestone Fees AccruedMilestoneFees	0	USD
CY2019	innt	Accrued Milestone Fees AccruedMilestoneFees	300000	USD
CY2019	innt	Adjustments To Additional Paid In Capital Allocation Of Warrants To Liabilities AdjustmentsToAdditionalPaidInCapitalAllocationOfWarrantsToLiabilities	3330000	USD
CY2018Q1	innt	Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents	913000	USD
CY2018	innt	Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents	913000	USD
CY2019Q4	innt	Capital Stock Authorized CapitalStockAuthorized	360000000	shares
CY2019Q4	innt	Class Of Warrant Or Right Number Of Shares Issued Per Warrant ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant	1.2	shares
CY2019Q4	innt	Class Of Warrant Or Right Number Of Shares Issued Per Warrant ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant	1.2	shares
CY2018	innt	Commissions Payable For Warrants Exercised CommissionsPayableForWarrantsExercised	87152	USD
CY2019	innt	Commissions Payable For Warrants Exercised CommissionsPayableForWarrantsExercised	0	USD
CY2018	innt	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	3077887	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30064	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-12174614	USD
CY2019	innt	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	0	USD
CY2018Q4	innt	Deferred Tax Assets Legal Fees DeferredTaxAssetsLegalFees	0	USD
CY2019Q4	innt	Deferred Tax Assets Legal Fees DeferredTaxAssetsLegalFees	111800	USD
CY2018	innt	Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Amount EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalAmount	-82300	USD
CY2019	innt	Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Amount EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalAmount	0	USD
CY2018	innt	Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Percent EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalPercent	0.003
CY2019	innt	Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Percent EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalPercent	0.000
CY2018Q3	innt	Estimated Clinical Trial Data Management Fee EstimatedClinicalTrialDataManagementFee	1100000	USD
CY2018Q1	innt	Exchange Ratio In Connection With Merger ExchangeRatioInConnectionWithMerger	0.37686604
CY2018	innt	Fair Value Net Derivative Asset Liability Measuredon Recurring Basis Unobservable Inputs Reconciliation Change In Derivative Liability FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputsReconciliationChangeInDerivativeLiability	50000	USD
CY2019	innt	Fair Value Net Derivative Asset Liability Measuredon Recurring Basis Unobservable Inputs Reconciliation Change In Derivative Liability FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputsReconciliationChangeInDerivativeLiability	873000	USD
CY2018	innt	Gain Losson Extinguishmentof Derivative Liability GainLossonExtinguishmentofDerivativeLiability	0	USD
CY2019	innt	Gain Losson Extinguishmentof Derivative Liability GainLossonExtinguishmentofDerivativeLiability	370000	USD
CY2016	innt	Milestone Fee Free Sales Target Value MilestoneFeeFreeSalesTargetValue	1500000000	USD
CY2019Q2	innt	Class Of Warrant Or Right Purchase Price Of Each Additional Warrant ClassOfWarrantOrRightPurchasePriceOfEachAdditionalWarrant	0.125
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001551986
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41324976	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	39500000	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	INNOVATE BIOPHARMACEUTICALS, INC.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019Q2	innt	Class Of Warrant Or Right Restriction Period ClassOfWarrantOrRightRestrictionPeriod	P45D
CY2018Q1	innt	Net Proceeds From Issuance Of Common Stock After Deducting Stock Issuance Costs NetProceedsFromIssuanceOfCommonStockAfterDeductingStockIssuanceCosts	16500000	USD
CY2018	innt	Noncash Accrued Interest Convertedto Convertible Note Payable NoncashAccruedInterestConvertedtoConvertibleNotePayable	156667	USD
CY2019	innt	Noncash Accrued Interest Convertedto Convertible Note Payable NoncashAccruedInterestConvertedtoConvertibleNotePayable	0	USD
CY2018	innt	Noncash Addition Of Deferred Offering Costs NoncashAdditionOfDeferredOfferingCosts	54706	USD
CY2018Q1	innt	Saleof Stock Stockholders Aggregate Shares Availableforsale SaleofStockStockholdersAggregateSharesAvailableforsale	13990403	shares
CY2019Q4	innt	Separation Agreements Number Of Former Executives SeparationAgreementsNumberOfFormerExecutives	2	executive
CY2019	innt	Noncash Addition Of Deferred Offering Costs NoncashAdditionOfDeferredOfferingCosts	151137	USD
CY2018	innt	Noncash Addition Of Derivative Liability NoncashAdditionOfDerivativeLiability	420000	USD
CY2019	innt	Severance Costs Equal Installment Period SeveranceCostsEqualInstallmentPeriod	P12M
CY2019	innt	Noncash Addition Of Derivative Liability NoncashAdditionOfDerivativeLiability	1281000	USD
CY2018	innt	Noncash Deferred Offering Costs Reclassifiedto Additional Paidin Capital NoncashDeferredOfferingCostsReclassifiedtoAdditionalPaidinCapital	159795	USD
CY2019	innt	Noncash Deferred Offering Costs Reclassifiedto Additional Paidin Capital NoncashDeferredOfferingCostsReclassifiedtoAdditionalPaidinCapital	0	USD
CY2018Q1	innt	Number Of Warrants Issued NumberOfWarrantsIssued	1400000	shares
CY2017Q4	innt	Operating Lease Annual Rental Payments OperatingLeaseAnnualRentalPayments	60000	USD
CY2017Q4	innt	Operating Lease Monthly Rental Payments OperatingLeaseMonthlyRentalPayments	5000	USD
CY2018Q1	innt	Placement Agent Fees PlacementAgentFees	1600000	USD
CY2018	innt	Repayments Of Shortterm Convertible Debt RepaymentsOfShorttermConvertibleDebt	275000	USD
CY2019	innt	Repayments Of Shortterm Convertible Debt RepaymentsOfShorttermConvertibleDebt	7790557	USD
CY2019	innt	Royalties Payment Expiration Requirement RoyaltiesPaymentExpirationRequirement	P10Y
CY2018Q1	innt	Saleof Stock Shares Issuable Upon Exerciseof Warrant SaleofStockSharesIssuableUponExerciseofWarrant	2051771	shares
CY2018Q1	innt	Saleof Stock Shelf Registration Maximum Equity Offering Price SaleofStockShelfRegistrationMaximumEquityOfferingPrice	175000000	USD
CY2018Q1	innt	Severance Provisions Annual Base Salary Period SeveranceProvisionsAnnualBaseSalaryPeriod	P12M
CY2018Q1	innt	Severance Provisions Continuation Of Health Insurance Benefits Period SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod	P12M
CY2019Q4	innt	Stock Issued During Period Shares Exerciseof Warrants StockIssuedDuringPeriodSharesExerciseofWarrants	3593714.4	shares
CY2019	innt	Stock Issued During Period Shares Warrant Exchange StockIssuedDuringPeriodSharesWarrantExchange	3593714	shares
CY2018	innt	Stock Issued During Period Value Stock Splits StockIssuedDuringPeriodValueStockSplits	-978674	USD
CY2019	innt	Stock Issued During Period Value Warrant Exchange StockIssuedDuringPeriodValueWarrantExchange	2012480	USD
CY2018	innt	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	841026	USD
CY2018	innt	Warrant Inducement Expense WarrantInducementExpense	0	USD
CY2019	innt	Warrant Inducement Expense WarrantInducementExpense	1265780	USD
CY2018Q4	innt	Warrant Liability Current WarrantLiabilityCurrent	0	USD
CY2019Q4	innt	Warrant Liability Current WarrantLiabilityCurrent	2637500	USD
CY2018Q1	innt	Warrant Term WarrantTerm	P5Y
CY2019Q2	innt	Warrants And Rights Outstanding Exercise Commencement Period WarrantsAndRightsOutstandingExerciseCommencementPeriod	P6M
CY2018	innt	Warrants Issued To Placement Agents WarrantsIssuedToPlacementAgents	913000	USD
CY2019	innt	Warrants Issued To Placement Agents WarrantsIssuedToPlacementAgents	0	USD
CY2018	innt	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	0	USD
CY2019	innt	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	100000	USD
CY2019	innt	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	100056	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3618634	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3890094	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	826327	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4747751	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26148	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47755	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39854297	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60946816	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3077887	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3805000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2871000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	0	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2569659	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	709442	USD
CY2019Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	41000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4592932	USD
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	104706	USD
CY2019Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	10300	USD
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1677600	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2000000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1995000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3805000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2871000	USD
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2513475	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1067379	USD
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9031318	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22822067	shares
CY2018Q4	us-gaap	Assets Assets	6454188	USD
CY2019Q4	us-gaap	Assets Assets	5296816	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	6413513	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	5222984	USD
CY2018Q4	us-gaap	Cash Cash	5728900	USD
CY2019Q4	us-gaap	Cash Cash	4592932	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	355563	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5728900	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5373337	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1135968	USD
CY2018Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	75000	USD
CY2019Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	75000	USD
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.13
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	15120898	shares
CY2019Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	3897010	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12981599	shares
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	25141814	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26088820	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39477667	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26088820	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39477667	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	2609	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	3948	USD
CY2018Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5196667	USD
CY2019Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3184655	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1716300	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4336800	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9857000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	39393000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	3551900	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4500	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	60100	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	224900	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	723800	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	723800	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2377400	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2805700	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	151800	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	122500	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8773000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15397200	USD
CY2018	us-gaap	Depreciation Depreciation	19555	USD
CY2019	us-gaap	Depreciation Depreciation	21607	USD
CY2018	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	50000	USD
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1243000	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	370000	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	408000	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.98
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.203
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.245
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.014
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.025
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.009
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.020
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	697334	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	574332	USD
CY2019Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	200000	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	54200	USD
CY2018	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	50000	USD
CY2019	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	1347900	USD
CY2019	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	-370000	USD
CY2017Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	0	USD
CY2018Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	370000	USD
CY2019Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	3045500	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1049166	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10664991	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10566813	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24162279	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27048808	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4921000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6624200	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5074100	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5680200	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	333600	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	89100	USD
CY2018	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	603900	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	41300	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-477200	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-534200	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	224900	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	540200	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	86412	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	124973	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-441050	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3921424	USD
CY2018	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-50000	USD
CY2019	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-873000	USD
CY2018	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-101624	USD
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	298724	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	50145	USD
CY2018	us-gaap	Interest Expense InterestExpense	6152043	USD
CY2019	us-gaap	Interest Expense InterestExpense	1825148	USD
CY2018	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	280394	USD
CY2019	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	0	USD
CY2018	us-gaap	Interest Income Other InterestIncomeOther	163832	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	185267	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	280287	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	874203	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	101624	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	60000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	45000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	45000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2170	USD
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2017Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2017Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6454188	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5296816	USD
CY2018	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	978674	USD
CY2019	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10113252	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14910830	USD
CY2019	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	3600000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20556610	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16843958	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13943	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11934	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15169330	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17967992	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-24162279	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-27048808	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5938211	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1500247	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	18224068	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	25548561	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	18224068	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	25548561	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	60000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	42830	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	42830	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42830	USD
CY2017Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P24M
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	42944800	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70842	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30150	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5580	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5580	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	50000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	57000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1706657	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1045468	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13943	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11934	USD
CY2018	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	75000	USD
CY2019	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	504907	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	555052	USD
CY2018	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	75000	USD
CY2019	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18100000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18132661	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20706919	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9700000	USD
CY2019Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7900000	USD
CY2018	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3345000	USD
CY2019	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	182428	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30064	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	928178	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61243	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	73177	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35095	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25422	USD
CY2019	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7559077	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13715968	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43515970	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70564778	USD
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4181068	shares
CY2019Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4318272	shares
CY2019	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	8499340	shares
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	5000	USD
CY2018	us-gaap	Severance Costs1 SeveranceCosts1	320000	USD
CY2019	us-gaap	Severance Costs1 SeveranceCosts1	300000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	3805000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2871000	USD
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.33
CY2019Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.025
CY2018	us-gaap	Stock Issued1 StockIssued1	9229819	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	9229819	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16182002	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20219756	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	182428	USD

Files In Submission

Name	View Source	Status
0001551986-20-000050-index-headers.html	Edgar Link	pending
0001551986-20-000050-index.html	Edgar Link	pending
0001551986-20-000050.txt	Edgar Link	pending
0001551986-20-000050-xbrl.zip	Edgar Link	pending
exhibit1023.htm	Edgar Link	pending
fig1.jpg	Edgar Link	pending
fig10.jpg	Edgar Link	pending
fig11.jpg	Edgar Link	pending
fig12.jpg	Edgar Link	pending
fig13.jpg	Edgar Link	pending
fig3.jpg	Edgar Link	pending
fig4.jpg	Edgar Link	pending
fig5.jpg	Edgar Link	pending
fig6.jpg	Edgar Link	pending
fig7.jpg	Edgar Link	pending
fig8.jpg	Edgar Link	pending
fig9.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
innovatebiopharmalogo1a02.jpg	Edgar Link	pending
innt-20191231.xml	Edgar Link	completed
innt-20191231.xsd	Edgar Link	pending
innt-20191231_cal.xml	Edgar Link	unprocessable
innt-20191231_def.xml	Edgar Link	unprocessable
innt-20191231_lab.xml	Edgar Link	unprocessable
innt-20191231_pre.xml	Edgar Link	unprocessable
innt1231201910-k.htm	Edgar Link	pending
inntex23-1mhmconsent.htm	Edgar Link	pending
inntex31-1.htm	Edgar Link	pending
inntex31-2.htm	Edgar Link	pending
inntex32-1.htm	Edgar Link	pending
inntex32-2.htm	Edgar Link	pending
inntex4-2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
table1.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

9 METERS BIOPHARMA, INC.

2020 Q1 Form 10-K Financial Statement

#000155198620000050 Filed on March 20, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission